GLP-1R agonist therapy for diabetes: benefits and potential risks.
about
Optimal therapy of type 2 diabetes: a controversial challengeAdvances in managing type 2 diabetes: challenging old paradigms and developing new ones.GLP-1(28-36)amide, the Glucagon-like peptide-1 metabolite: friend, foe, or pharmacological folly?Effects of glucagon-like peptide-1 receptor agonists on renal functionLiraglutide Versus Lixisenatide: Long-Term Cost-Effectiveness of GLP-1 Receptor Agonist Therapy for the Treatment of Type 2 Diabetes in SpainAn updated review on cancer risk associated with incretin mimetics and enhancers.Differential effects of prandial and non-prandial GLP-1 receptor agonists in type 2 diabetes therapy.GLP-1 Receptor Agonists: Practical Considerations for Clinical Practice.Safety and efficacy of a glucagon-like peptide-1 receptor agonist added to basal insulin therapy versus basal insulin with or without a rapid-acting insulin in patients with type 2 diabetes: results of a meta-analysis.Peripheral actions of GPCRs in energy homeostasis: view from the Chair.
P2860
Q33577712-A39274A9-2E53-427F-A9B9-CE7AB1827EE2Q33720446-18571E95-9BBF-4830-8586-13804587EEFDQ33734024-343D9432-BE6A-4510-BB34-9351DB91E74BQ37232679-54DE62E2-A1A5-49AA-8C8A-AF66519AB546Q37737468-1EE4EB41-95CF-4AF0-A80C-5B696F982325Q38388920-632E1D45-8DC0-459A-B2EA-68FC9664A6E4Q38597109-97C74A37-C309-48CD-A959-4B19EDC98A5FQ38602769-CBDB3AD5-1CF0-462B-96A9-E7D7D099EABAQ38907259-8796FAA6-BA18-4238-93FF-373AA23A46BFQ39789645-BAE8A146-845A-4560-9907-0493CE7BF189
P2860
GLP-1R agonist therapy for diabetes: benefits and potential risks.
description
2013 nî lūn-bûn
@nan
2013 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2013 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
name
GLP-1R agonist therapy for diabetes: benefits and potential risks.
@ast
GLP-1R agonist therapy for diabetes: benefits and potential risks.
@en
GLP-1R agonist therapy for diabetes: benefits and potential risks.
@nl
type
label
GLP-1R agonist therapy for diabetes: benefits and potential risks.
@ast
GLP-1R agonist therapy for diabetes: benefits and potential risks.
@en
GLP-1R agonist therapy for diabetes: benefits and potential risks.
@nl
prefLabel
GLP-1R agonist therapy for diabetes: benefits and potential risks.
@ast
GLP-1R agonist therapy for diabetes: benefits and potential risks.
@en
GLP-1R agonist therapy for diabetes: benefits and potential risks.
@nl
P1476
GLP-1R agonist therapy for diabetes: benefits and potential risks.
@en
P2093
Alan Garber
Susan L Samson
P356
10.1097/MED.0B013E32835EDB32
P577
2013-04-01T00:00:00Z